AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development (Q42843248)

8 November 2017

0 references

AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development (English)

1 reference

8 November 2017

0 references

Sandhya Girish

1

1 reference

8 November 2017

Steven W Martin

2

1 reference

8 November 2017

Mark C Peterson

3

1 reference

8 November 2017

Lei K Zhang

4

1 reference

8 November 2017

Hong Zhao

5

1 reference

8 November 2017

Joseph Balthasar

6

1 reference

8 November 2017

Raymond Evers

7

1 reference

8 November 2017

Honghui Zhou

8

1 reference

8 November 2017

Min Zhu

9

1 reference

8 November 2017

Lewis Klunk

10

1 reference

8 November 2017

Chao Han

11

1 reference

8 November 2017

Eva Gil Berglund

12

1 reference

8 November 2017

Shiew-Mei Huang

13

1 reference

8 November 2017

Amita Joshi

14

1 reference

8 November 2017

language of work or name

English

0 references

publication date

1 June 2011

1 reference

8 November 2017

1 reference

8 November 2017

13

1 reference

8 November 2017

3

1 reference

8 November 2017

405-416

1 reference

Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review

8 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Membrane transporters in drug development

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Drug interaction studies of therapeutic proteins or monoclonal antibodies

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Regulation of drug-metabolizing enzymes and transporters in inflammation

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3144367

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

16 August 2018

1 reference

12 December 2020

OKT3 therapy increases cyclosporine blood levels

1 reference

12 December 2020

Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy

1 reference

12 December 2020

Down-regulation of activating Fcgamma receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment

1 reference

12 December 2020

Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis

1 reference

12 December 2020

Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice

1 reference

12 December 2020

Transporters in drug development: advancing on the Critical Path

1 reference

12 December 2020

Therapeutic protein-drug interactions and implications for drug development

1 reference

12 December 2020

In vivo effects of interleukin-10 on human cytochrome P450 activity

1 reference

12 December 2020

Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients

1 reference

12 December 2020

Effects of interferon-alpha on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C

1 reference

12 December 2020

10.1208/S12248-011-9285-6

Identifiers

DOI

1 reference

Dimensions Publication ID

8 November 2017

0 references

1 reference

8 November 2017

PubMed publication ID

21630127

1 reference